This document provides methods and materials for treating a mammal having HER2-expressing cancers. For example, antibody drug conjugates containing an anti-HER2 antibody and at least one molecule of an anti-cancer drug are provided, as well as methods of administering such antibody drug conjugates to a mammal (e.g., a human) having a HER2-expressing cancer to treat the mammal.